Results from a study exploring the role of the microRNA biomarker miR-31-3p in patients with advanced adenocarinoma of the lung were presented during the 2015 European Lung Cancer Conference (ELCC) held in Geneva, Switzerland. The data presented demonstrated that the expression of miR-31-3p is associated with the histological type of the lung tumor, with a higher expression of the biomarker in mucinous type, and also identifies patients with a shorter progression-free survival. The results also indicate that miR-31-3p is associated with overall survival and disease control rate in a subgroup of patients with advanced non-small cell lung cancer (NSCLC) treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI). The data presented was based on a post-hoc analysis of patients enrolled in two prospective, randomized controlled phase II trials of EGFR TKIs in patients with non-resectable pneumonic adenocarcinoma which were conducted by the French Cooperative Thoracic Intergroup (IFCT).
Click here to view press release